Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Multiple sclerosis failed clinical trials

Fig. 5. Structures of (A) CP-481,715, (B) BX 471, and (C) T487. CP-481,715 and BX 471 are specific CCR1 antagonists from Pfizer and Berlex/Schering AG, and both failed to exhibit efficacy for rheumatoid arthritis and multiple sclerosis, respectively, in phase II trials. T487 is a specific CXCR3 antagonist from Amgen/Turalik that failed in phase Ha psoriasis clinical trials due to lack of efficacy. Fig. 5. Structures of (A) CP-481,715, (B) BX 471, and (C) T487. CP-481,715 and BX 471 are specific CCR1 antagonists from Pfizer and Berlex/Schering AG, and both failed to exhibit efficacy for rheumatoid arthritis and multiple sclerosis, respectively, in phase II trials. T487 is a specific CXCR3 antagonist from Amgen/Turalik that failed in phase Ha psoriasis clinical trials due to lack of efficacy.
See other pages where Multiple sclerosis failed clinical trials is mentioned: [Pg.97]    [Pg.344]    [Pg.354]    [Pg.354]    [Pg.382]    [Pg.354]    [Pg.354]    [Pg.66]    [Pg.109]    [Pg.183]    [Pg.461]    [Pg.326]    [Pg.179]   
See also in sourсe #XX -- [ Pg.594 , Pg.595 ]

See also in sourсe #XX -- [ Pg.594 ]



SEARCH



Failed Clinical Trials

Multiple Sclerosis

Multiple sclerosis trials

Sclerosis

© 2024 chempedia.info